Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Kumar Nathan who wrote (265)	2/9/1997 10:32:00 PM
From: John Metcalf	of 6136

The possibility of a share price retreat after Viracept approval is a logical function of strong focus on Viracept in the business press. Not that much is known about Thymitaq, the Roche deals, MMPI, or GART. Though there are strong indicators that Viracept will sell well and will be profitable, that's not the same as earnings in hand. As the rest of Agouron's pipeline becomes better known, and as Viracept earns a profit for the company, new waves of stock price appreciation will ensue. I'm not selling on a retreat -- the risk of being out of the stock is greater IMHO, than the attraction of profit-taking.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next